

# A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Genentech, Inc.
Enrollment	250 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
  - Life expectancy  $\geq$  3 months, in the investigator's judgment
  - Adequate hematologic and end-organ function
  - Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care
  - Measurable disease per RECIST v1.1
- ... and 1 more (see full listing online)

### Exclusion (10)

- Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions
  - Active hepatitis B or C
  - Active tuberculosis
  - Positive test for human immunodeficiency virus (HIV) infection
  - Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion
- ... and 5 more (see full listing online)

## Locations (18 total)

---

University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States  
Yale Cancer Center, New Haven, Connecticut, United States  
Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States  
... and 15 more locations